Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.
At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.